Skip to content
Head to head

Halozyme Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: HALO · VRTX

Updated 9 minutes ago

1-year performance, rebased to 100

HALO +29.5%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
HALOVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price91.35515.02
Change today-1.82%-1.08%
1-year return+32.4%+22.0%
Market cap$10.41B$130.58B
52-week range61.23 – 134.00412.27 – 568.67
Valuation
P/E (TTM)22.8433.14
P/E percentile, own 5-yr range65th99th
P/B-188.356.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)2.5615.32
Net profit (TTM)$291.87M$3.88B
Revenue (TTM)$1.80B$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+39.2%+11.8%
Gross margin82.3%85.5%
Operating margin55.9%33.1%
Net margin26.9%30.7%
Free cash flow (TTM)$598.10M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership114.0%96.8%
Insider activity (12mo)26 buy / 24 sell28 buy / 22 sell
Short interest (% of float)12.0%1.9%
Analyst consensus80% buy / 20% hold (5)95% buy / 5% hold (21)
Analyst price target$126 (+37%)$624 (+21%)
StockVane view
StockVane Quant RatingC (75)C (68)
Company
Employees4236,400
Founded19981989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.